Although the appropriate phage for patients with COVID-19 to accept pharmacological interventions is worth exploring, much remains obscure regarding potential agonists to provide a host for pyroptosis Downstream cytokine antagonists may have advantages in treating COVID-19, given that the overexpression of IL-1β, specifically in the lungs, is sufficient to recapitulate many of the ARDS phenotypes (90). The gene discussed is IL1B; the disease is COVID-19.